Clinical Cancer Research, Vol 4, Issue 1 229-234, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Telomerase enzyme activity and RNA expression during the multistage pathogenesis of breast carcinoma

K Yashima, S Milchgrub, LS Gollahon, A Maitra, MH Saboorian, JW Shay and AF Gazdar
Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas 75235-8593, USA.

Telomerase, an RNA-containing enzyme, is associated with cellular immortality and malignancy. We investigated the role of telomerase during the multistage pathogenesis of breast cancer. We used the semiquantitative, PCR-based telomeric repeat amplification protocol assay for enzyme activity (42 specimens from 42 patients) and a radioactive in situ assay for expression of its RNA component (human telomerase RNA; hTR) for the identification of telomerase-positive cells in archival resection samples (n = 67 from 39 patients). Low telomerase activity was detected in 1 (14%) of 7 samples of benign breast disease, in 4 (67%) of 6 fibroadenomas, in 11 (92%) of 12 carcinoma in situ (CIS) lesions, and in 16 (94%) of 17 invasive breast cancers. There was a progressive increase in the mean telomerase levels with progressive increase in severity of histopathological change (P < 0.05). Almost all of 67 resection samples expressed hTR, irrespective of histology. Expression was low to moderate in some samples of normal epithelium and nonproliferative fibrocystic changes. hTR expression was limited to epithelial cells; expression in stromal cells, including those in fibroadenomas, was negative. Increased hTR expression was observed in some foci of apocrine metaplasia and atypical hyperplasia. Increased hTR expression was also observed in all CIS and invasive lesions, although considerable heterogeneity was noted. Focal up-regulation was frequently noted in CIS lesions in the vicinity of invasive tumors. Thus, up-regulation of hTR may be a predictive marker for invasive tumor development.

This article has been cited by other articles:

				M. Kedde, C. le Sage, A. Duursma, E. Zlotorynski, B. van Leeuwen, W. Nijkamp, R. Beijersbergen, and R. Agami Telomerase-independent Regulation of ATR by Human Telomerase RNA J. Biol. Chem., December 29, 2006; 281(52): 40503 - 40514. [Abstract] [Full Text] [PDF]

				M. A. Cerone, J. A. Londono-Vallejo, and C. Autexier Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells. Mol. Cancer Ther., July 1, 2006; 5(7): 1669 - 1675. [Abstract] [Full Text] [PDF]

				L. Ai, Q. Tao, S. Zhong, C.R. Fields, W.-J. Kim, M. W. Lee, Y. Cui, K. D. Brown, and K. D. Robertson Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer Carcinogenesis, July 1, 2006; 27(7): 1341 - 1348. [Abstract] [Full Text] [PDF]

				S. Trapp, M. S. Parcells, J. P. Kamil, D. Schumacher, B. K. Tischer, P. M. Kumar, V. K. Nair, and N. Osterrieder A virus-encoded telomerase RNA promotes malignant T cell lymphomagenesis J. Exp. Med., May 15, 2006; 203(5): 1307 - 1317. [Abstract] [Full Text] [PDF]

				S. Lantuejoul, J. C. Soria, L. Morat, P. Lorimier, D. Moro-Sibilot, L. Sabatier, C. Brambilla, and E. Brambilla Telomere Shortening and Telomerase Reverse Transcriptase Expression in Preinvasive Bronchial Lesions Clin. Cancer Res., March 1, 2005; 11(5): 2074 - 2082. [Abstract] [Full Text] [PDF]

				B.-S. Herbert, V. P. Pearce, L. S. Hynan, D. M. LaRue, W. E. Wright, L. Kopelovich, and J. W. Shay A Peroxisome Proliferator-activated Receptor-{gamma} Agonist and the p53 Rescue Drug CP-31398 Inhibit the Spontaneous Immortalization of Breast Epithelial Cells Cancer Res., April 15, 2003; 63(8): 1914 - 1919. [Abstract] [Full Text] [PDF]

				J. W. Shay, Y. Zou, E. Hiyama, and W. E. Wright Telomerase and cancer Hum. Mol. Genet., April 1, 2001; 10(7): 677 - 685. [Abstract] [Full Text] [PDF]

				V. Rohde, H.-P. Sattler, T. Bund, H. Bonkhoff, T. Fixemer, C. Bachmann, R. Lensch, G. Unteregger, M. Stoeckle, and B. Wullich Expression of the Human Telomerase Reverse Transcriptase Is Not Related to Telomerase Activity in Normal and Malignant Renal Tissue Clin. Cancer Res., December 1, 2000; 6(12): 4803 - 4809. [Abstract] [Full Text]

				T. Günther, R. Schneider-Stock, C. Häckel, M. Pross, H.-U. Schulz, H. Lippert, and A. Roessner Telomerase Activity and Expression of hTRT and hTR in Gastrointestinal Stromal Tumors in Comparison with Extragastrointestinal Sarcomas Clin. Cancer Res., May 1, 2000; 6(5): 1811 - 1818. [Abstract] [Full Text]

				P. Rudolph, C. Schubert, S. Tamm, K. Heidorn, A. Hauschild, I. Michalska, S. Majewski, G. Krupp, S. Jablonska, and R. Parwaresch Telomerase Activity in Melanocytic Lesions : A Potential Marker of Tumor Biology Am. J. Pathol., April 1, 2000; 156(4): 1425 - 1432. [Abstract] [Full Text] [PDF]

				L. A. Carey, N. W. Kim, S. Goodman, J. Marks, G. Henderson, C. B. Umbricht, J. S. Dome, W. Dooley, S. R. Amshey, and S. Sukumar Telomerase Activity and Prognosis in Primary Breast Cancers J. Clin. Oncol., October 1, 1999; 17(10): 3075 - 3081. [Abstract] [Full Text] [PDF]

				M. Saji, S. Xydas, W. H. Westra, C.-K. Liang, D. P. Clark, R. Udelsman, C. B. Umbricht, S. Sukumar, and M. A. Zeiger Human Telomerase Reverse Transcriptase (hTERT) Gene Expression in Thyroid Neoplasms Clin. Cancer Res., June 1, 1999; 5(6): 1483 - 1489. [Abstract] [Full Text] [PDF]